『Breakthrough Malaria Vaccines Show 75% Risk Reduction and Transform Child Health in Nigeria』のカバーアート

Breakthrough Malaria Vaccines Show 75% Risk Reduction and Transform Child Health in Nigeria

Breakthrough Malaria Vaccines Show 75% Risk Reduction and Transform Child Health in Nigeria

無料で聴く

ポッドキャストの詳細を見る

概要

 Researchers from the Walter and Eliza Hall Institute (WEHI) and Burnet Institute have identified key immune targets for a Plasmodium vivax malaria vaccine, according to a study published in Immunity and reported by Technology Networks. The research, co-led by Dr. Rhea Longley and Professor Ivo Mueller, analyzed blood samples from children in Papua New Guinea, revealing that functional antibodies targeting multiple parasite proteins can reduce malaria risk by over 75 percent. Unlike Plasmodium falciparum, which has existing vaccines, P. vivax's dormant liver stage complicates elimination, and this work provides a blueprint for vaccine design by showing how antibodies recruit immune cells to attack the parasite.

In Nigeria's Kebbi State, the R21 malaria vaccine has dramatically cut child hospitalizations and deaths one year after rollout, as detailed in a Gavi VaccinesWork article dated March 2, 2026. Over 200,000 children aged 5 to 23 months received at least a first dose starting December 2024, with health centers reporting up to 50 percent fewer malaria cases. At Nassarawa Maternal and Child Health Centre, weekly admissions dropped from 12 to four, with no child malaria deaths since June 2025, according to health worker Maimunatu Abubakar. Takalau Primary Health Centre saw monthly cases halve from 40 to 15-20, per facility head Shuaibu Umar. Statewide, under-five mortality fell from 8.97 percent to 6.13 percent between January and October 2025, credited to the vaccine by Kebbi Primary Health Care Development Agency executive secretary Abubakar Muhammed Noma. Parents like Nafisa Mohammad report their vaccinated children, such as two-year-old Ibrahim, avoiding malaria bouts that previously strained families.

These advances highlight growing momentum against malaria, though challenges persist. Benin is addressing antimalarial drug resistance alongside RTS,S vaccine use, as noted in a Table.media feature on March 3, 2026, emphasizing new drugs like GanLum. In the Americas, PAHO Director Jarbas Barbosa highlighted Suriname's recent malaria elimination in a February 26 podcast, underscoring regional progress amid ongoing outbreaks. With Nigeria bearing 27 percent of global cases, such vaccine successes signal hope for broader control.

This content was created in partnership and with the help of Artificial Intelligence AI
まだレビューはありません